B-cell Non-Hodgkin Lymphoma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – AbbVie, Genmab, Novartis, AstraZeneca

Posted on
by

B-cell Non-Hodgkin Lymphoma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - AbbVie, Genmab, Novartis, AstraZeneca
DelveInsight’s “B-cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the B-cell Non-Hodgkin Lymphoma.

DelveInsight’s “B-cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the B-cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the B-cell Non-Hodgkin Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; B-cell Non-Hodgkin Lymphoma Market Forecast

 

Some of the key facts of the B-cell Non-Hodgkin Lymphoma Market Report: 

  • The B-cell Non-Hodgkin Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the American cancer society, about 80,470 people (44,120 males and 36,350 females) will be diagnosed with NHL in the year 2022. This includes both adults and children SEER, 2020, estimated that there would be near to 77,240 new cases of NHL in 2020 in the United States
  • B-cell lymphomas make up most (about 85%) of the NHL cases. Among the 7MM, our estimates shows that the highest Incident population of B cell-NHL was in the United States
  • According to a study by Gena Kanas et al. (2021), the number of incident DLBCL cases in the US is projected   from 29,108 to 32,443 and from 26,078 to 27,981 in WE (Western Europe) from 2020 to 2025, with a total rate of increase of 11% in the US compared to 7% in the WE
  • Key B-cell Non-Hodgkin Lymphoma Companies: AbbVie, Genmab, Novartis, AstraZeneca, Pacylex Pharma, Hutchison Medipharma, AbClon, Genmab, Hoffmann-La Roche, Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Regeneron Pharmaceuticals, ADC Therapeutics S.A., Jiangsu HengRui, Takeda, and others
  • Key B-cell Non-Hodgkin Lymphoma Therapies: Epcoritamab, Cyclophosphamide, GP2013, Capivasertib, PCLX-001, HMPL-760, AT101, rituximab, Mosunetuzumab, ME-401, Tazemetostat, Odronextamab, Loncastuximab Tesirine, SHR1459, TAK-007, and others
  • The B-cell Non-Hodgkin Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage B-cell Non-Hodgkin Lymphoma pipeline products will significantly revolutionize the B-cell Non-Hodgkin Lymphoma market dynamics.

 

B-cell Non-Hodgkin Lymphoma Overview

NHL represents a heterogeneous group of malignancies of different biology and prognosis and can be divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can develop from either B-cells or T-cells. Lymphomas that occur after allogeneic bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas.

 

Get a Free sample for the B-cell Non-Hodgkin Lymphoma Market Report – 

https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market

 

B-cell Non-Hodgkin Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

B-cell Non-Hodgkin Lymphoma Epidemiology Segmentation:

The B-cell Non-Hodgkin Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of B-cell Non-Hodgkin Lymphoma
  • Prevalent Cases of B-cell Non-Hodgkin Lymphoma by severity
  • Gender-specific Prevalence of B-cell Non-Hodgkin Lymphoma
  • Diagnosed Cases of Episodic and Chronic B-cell Non-Hodgkin Lymphoma

 

Download the report to understand which factors are driving B-cell Non-Hodgkin Lymphoma epidemiology trends @ B-cell Non-Hodgkin Lymphoma Epidemiology Forecast

 

B-cell Non-Hodgkin Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the B-cell Non-Hodgkin Lymphoma market or expected to get launched during the study period. The analysis covers B-cell Non-Hodgkin Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the B-cell Non-Hodgkin Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

B-cell Non-Hodgkin Lymphoma Therapies and Key Companies

  • Epcoritamab: AbbVie
  • Cyclophosphamide: Genmab
  • GP2013: Novartis
  • Capivasertib: AstraZeneca
  • PCLX-001: Pacylex Pharma
  • HMPL-760: Hutchison Medipharma
  • AT101: AbClon
  • rituximab: Genmab
  • Mosunetuzumab: Hoffmann-La Roche
  • ME-401: Kyowa Kirin Co.
  • Tazemetostat: Eisai Co.
  • Odronextamab: Regeneron Pharma
  • Loncastuximab: Tesirine
  • SHR1459: Jiangsu HengRui
  • TAK-007: Takeda

 

Discover more about therapies set to grab major B-cell Non-Hodgkin Lymphoma market share @ B-cell Non-Hodgkin Lymphoma Treatment Market

 

Scope of the B-cell Non-Hodgkin Lymphoma Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key B-cell Non-Hodgkin Lymphoma Companies: AbbVie, Genmab, Novartis, AstraZeneca, Pacylex Pharma, Hutchison Medipharma, AbClon, Genmab, Hoffmann-La Roche, Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Regeneron Pharmaceuticals, ADC Therapeutics S.A., Jiangsu HengRui, Takeda, and others
  • Key B-cell Non-Hodgkin Lymphoma Therapies: Epcoritamab, Cyclophosphamide, GP2013, Capivasertib, PCLX-001, HMPL-760, AT101, rituximab, Mosunetuzumab, ME-401, Tazemetostat, Odronextamab, Loncastuximab Tesirine, SHR1459, TAK-007, and others
  • B-cell Non-Hodgkin Lymphoma Therapeutic Assessment: B-cell Non-Hodgkin Lymphoma current marketed and B-cell Non-Hodgkin Lymphoma emerging therapies
  • B-cell Non-Hodgkin Lymphoma Market Dynamics: B-cell Non-Hodgkin Lymphoma market drivers and B-cell Non-Hodgkin Lymphoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • B-cell Non-Hodgkin Lymphoma Unmet Needs, KOL’s views, Analyst’s views, B-cell Non-Hodgkin Lymphoma Market Access and Reimbursement 

 

To know more about B-cell Non-Hodgkin Lymphoma companies working in the treatment market, visit @ B-cell Non-Hodgkin Lymphoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. B-cell Non-Hodgkin Lymphoma Market Report Introduction

2. Executive Summary for B-cell Non-Hodgkin Lymphoma

3. SWOT analysis of B-cell Non-Hodgkin Lymphoma

4. B-cell Non-Hodgkin Lymphoma Patient Share (%) Overview at a Glance

5. B-cell Non-Hodgkin Lymphoma Market Overview at a Glance

6. B-cell Non-Hodgkin Lymphoma Disease Background and Overview

7. B-cell Non-Hodgkin Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of B-cell Non-Hodgkin Lymphoma 

9. B-cell Non-Hodgkin Lymphoma Current Treatment and Medical Practices

10. B-cell Non-Hodgkin Lymphoma Unmet Needs

11. B-cell Non-Hodgkin Lymphoma Emerging Therapies

12. B-cell Non-Hodgkin Lymphoma Market Outlook

13. Country-Wise B-cell Non-Hodgkin Lymphoma Market Analysis (2019–2032)

14. B-cell Non-Hodgkin Lymphoma Market Access and Reimbursement of Therapies

15. B-cell Non-Hodgkin Lymphoma Market Drivers

16. B-cell Non-Hodgkin Lymphoma Market Barriers

17.  B-cell Non-Hodgkin Lymphoma Appendix

18. B-cell Non-Hodgkin Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services